poly(ADP-ribose) polymerase family member 4Genealiases: ADPRTL1 · ARTD4 · PARP-4 · PARPL · PH5P · VAULT3
Q-omics provides the consensus-scored PARP4 profile across patient tissues and cancer cell-line models. PARP4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PARP4 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PARP4 protein abundance shows 28,248 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where PARP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP4 survival associations across molecular data types. PARP4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP4 RNA expression–survival associations across cancer types. High PARP4 expression shows unfavorable associations in CESC, PAAD and LGG, but favorable associations in KIRC, SKCM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PARP4 RNA expression.
This table summarizes PARP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PARP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP4 shows lower tumor expression in KICH and LUSC and higher tumor expression in LIHC, THCA, CHOL and PAAD. The KICH box plot shows higher PARP4 RNA expression in normal versus tumor tissue (log2 FC = −1.725, t-test p < 0.001).
This table shows molecular features associated with PARP4 in patient tissues and cancer cell lines. In patient samples, PARP4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
